Last €6.60 EUR
Change Today -0.10 / -1.49%
Volume 541.0
As of 11:26 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

txcell (TXCL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/2/14 - €8.10
52 Week Low
04/14/14 - €5.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TXCELL (TXCL)

Related News

No related news articles were found.

txcell (TXCL) Related Businessweek News

No Related Businessweek News Found

txcell (TXCL) Details

TxCell Promesses develops cell-based immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases. The company’s product candidates include OvaSave, which has completed phase I/II clinical trials for the treatment of severe refractory Crohn’s disease; and Col-Treg, which is under preclinical stage for the treatment of autoimmune uveitis. Its other product candidates include Myelin that is under development for the treatment of central nervous system inflammatory diseases; and HSP60, which is under development for the treatment of autoimmune and inflammatory diseases. The company was formerly known as TxCell S.A. and changed its name to TxCell Promesses in April 2014. TxCell Promesses was founded in 2001 and is headquartered in Valbonne, France.

36 Employees
Last Reported Date: 04/2/14
Founded in 2001

txcell (TXCL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

txcell (TXCL) Key Developments

TxCell Reports Revenue Results for the Second Quarter and First Half Ended June 30, 2014

TxCell reported revenue results for the second quarter and first half ended June 30, 2014. For the period, the company reported generated revenues of EUR 162,000 compared with no reported revenues during the same period in 2013. For the quarter, the company reported revenue of EUR 82,000.

TxCell Promesses Presents at BIO International Convention, Jun-23-2014

TxCell Promesses Presents at BIO International Convention, Jun-23-2014 . Venue: San Diego Convention Center, San Diego, California, United States.

TxCell Promesses(ENXTPA:TXCL) added to Next Biotech Index

TxCell Promesses will be added to the Next Biotech Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TXCL:FP €6.60 EUR -0.10

TXCL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TXCL.
View Industry Companies

Industry Analysis


Industry Average

Valuation TXCL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TXCELL, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at